title: Splenectomy may improve the glomerulopathy of type II mixed cryoglobulinemia.
abstract: Many patients with type II mixed cryoglobulinemia have been shown to be infected with hapatitis C virus (HCV). Therefore, interferon-alfa has become the first choice of treatment for patients with HCV-associated cryoglobulinemia. However, the disease often relapses after the discontinuation of interferon therapy. The long-term effect of interferon therapy is controversial. Therefore, a more effective therapy needs to be developed. A 62-year-old Japanese woman was admitted to our hospital for the examination of abnormal liver function tests, severe edema, and purpura in her lower extremities. Glomerulopathy secondary to HCV-related cryoglobulinemia was suspected. Her serum creatinine was increased to 2.1 mg/dL. Interferon therapy was considered initially. However, because of pancytopenia caused by liver cirrhosis and splenomegaly, splenectomy was performed in February 1997, before the start of interferon therapy. Renal biopsy specimen taken at the time of the splenectomy showed typical cryoglobulinemic glomerulonephritis. Gradually, after surgery, the patient's thrombocytopenia and anemia improved, her proteinuria and hematuria were decreased, her cryocrit dropped from 15% to 5%, the Ccr increased from 21.1 mL/min to 48.8 mL/min, and the purpura in her lower extremities disappeared. A repeat renal biopsy performed in May 1998 showed marked histological improvement. Splenectomy is not widely accepted as a treatment for cryoglobulinemia. Our case suggests the possibility that the monoclonal-IgM component of the type II cryoglobulin may be formed in the spleen. In conclusion, splenectomy may be an effective therapy for cryoglobulinemia in patients with HCV-positive liver cirrhosis and pancytopenia secondary to splenomegaly.
authors.affiliation: Nephrology Center, Department of Pathology and Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan. ubara@ma.kcom.ne.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Ubara
authors.forename: S
authors.initials: S
authors.lastname: Hara
authors.forename: H
authors.initials: H
authors.lastname: Katori
authors.forename: T
authors.initials: T
authors.lastname: Tagami
authors.forename: A
authors.initials: A
authors.lastname: Kitamura
authors.forename: M
authors.initials: M
authors.lastname: Yokota
authors.forename: Y
authors.initials: Y
authors.lastname: Matsushita
authors.forename: F
authors.initials: F
authors.lastname: Takemoto
authors.forename: A
authors.initials: A
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Nagahama
authors.forename: M
authors.initials: M
authors.lastname: Hara
authors.forename: K
authors.initials: K
authors.lastname: Chayama
mesh_terms: D000740:Anemia / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000276:immunology; D001706:Biopsy; D003404:Creatinine / Q000097:blood; D003449:Cryoglobulinemia / Q000145:classification* / Q000821:virology; D003450:Cryoglobulins / Q000032:analysis; D005260:Female; D005921:Glomerulonephritis / Q000209:etiology / Q000628:therapy*; D006417:Hematuria / Q000628:therapy; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D008103:Liver Cirrhosis / Q000209:etiology; D008875:Middle Aged; D010198:Pancytopenia / Q000209:etiology; D011507:Proteinuria / Q000628:therapy; D013154:Spleen / Q000276:immunology; D013156:Splenectomy; D013163:Splenomegaly / Q000209:etiology; D013921:Thrombocytopenia / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D003450:Cryoglobulins; D007075:Immunoglobulin M; D003404:Creatinine